Axcella Announces Upcoming Investor Conference Presentation
Axcella (Nasdaq: AXLA) announced participation in a fireside chat at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 1:30 p.m. ET. The discussion will be streamed live on the company’s website, with a replay available for 30 days post-event. Axcella is focusing on developing innovative treatments using endogenous metabolic modulator compositions for complex diseases, particularly targeting non-alcoholic steatohepatitis (NASH) and reducing the risk of overt hepatic encephalopathy recurrence. For more details, visit www.axcellahealth.com.
- None.
- None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in a fireside chat at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020 at 1:30 p.m. ET.
A live audio webcast of this discussion will be available on the “Investors & News” section of the company’s website, www.axcellahealth.com. A replay will also be available on Axcella’s website for 30 days following the presentation.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.
